ArticleFrontiers in oncology2026
MRI patterns of non-enhancing T2-FLAIR hyperintense lesions with dynamic change in primary CNS lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The nature of non-enhancing T2-FLAIR hyperintense lesions that are not contiguous with the enhancing tumor site at baseline in primary central nervous system lymphoma (PCNSL) remains unclear. Our aim was to explore the incidence, location, morphology, and dynamic changes of these non-enhancing T2-FLAIR hyperintense lesions in PCNSL. Methods: We retrospectively reviewed patients diagnosed with immunocompetent PCNSL at our institution. We identified and evaluated T2-FLAIR hyperintense lesions without enhancement that showed a marked decrease or complete disappearance on MRI after treatment. MRI characteristics of PCNSL at initial presentation were analyzed and compared between patients with and without non-enhancing T2-FLAIR hyperintense lesions. Results: Among 87 patients, 10 patients (11.5%) were found to have non-enhancing T2-FLAIR hyperintense lesions located at a distance from the enhancing tumor site at baseline that showed a marked decrease or disappearance after treatment. The locations of these lesions were as follows: the juxtacortical and deep white matter (7 lesions), periventricular white matter (2 lesions), basal ganglia (1 lesion), and infratentorial area (1 lesion). Baseline MRI characteristics in patients with non-enhancing T2-FLAIR hyperintense lesions exhibited a higher rate of multiple enhancing lesions (P = 0.027) and bilateral enhancing lesions (P = 0.011) compared to patients without non-enhancing T2-FLAIR hyperintense lesions. Conclusion: In PCNSL patients, non-enhancing T2-FLAIR hyperintense lesions at a distance from enhancing tumor lesions, which are potentially neoplastic in nature, were not uncommon. Our findings raise the question of whether these non-enhancing lesions should be incorporated into the initial evaluation of tumor burden. This issue warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.